Related Experiment Video
Updated: May 10, 2026

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus
Published on: December 7, 2013
Atherosclerosis in systemic lupus erythematosus
George Stojan1, Michelle Petri
1Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
Insights
Systemic lupus erythematosus (SLE) patients face accelerated atherosclerosis and mortality. While traditional risk factors are important, SLE-specific factors and certain treatments like hydroxychloroquine are key for managing cardiovascular risk in these patients.
Area of Science:
- Cardiovascular Medicine
- Rheumatology
- Immunology
Background:
- Accelerated atherosclerosis is a primary cause of mortality in Systemic Lupus Erythematosus (SLE) patients.
- Traditional cardiovascular risk factors inadequately explain the elevated risk in SLE.
- SLE-specific factors, including disease activity, duration, corticosteroid use, and antiphospholipid antibodies, significantly contribute to cardiovascular risk.
Purpose of the Study:
- To review the cardiovascular risk factors and management strategies in patients with Systemic Lupus Erythematosus.
- To evaluate the efficacy of various therapeutic interventions on cardiovascular outcomes in SLE.
Main Methods:
- Literature review of studies on cardiovascular disease in SLE.
- Analysis of traditional and SLE-specific risk factors for atherosclerosis.
- Evaluation of pharmacological interventions, including statins, hydroxychloroquine, mycophenolate mofetil, vitamin D, and homocysteine treatments.
Main Results:
- Statins show limited efficacy in preventing cardiovascular outcomes in SLE populations.
- Hydroxychloroquine demonstrates cardioprotective effects.
- Mycophenolate mofetil may reduce cardiovascular events, supported by preclinical and transplant data.
- The benefits of vitamin D supplementation and hyperhomocysteinemia treatment remain debated but are considered optional therapies due to safety profiles.
Conclusions:
- Systemic Lupus Erythematosus is considered a coronary heart disease equivalent, necessitating aggressive management of all risk factors.
- Hydroxychloroquine and potentially mycophenolate mofetil are beneficial for cardiovascular health in SLE patients.
- Further research is needed to clarify the role of vitamin D and homocysteine management in SLE cardiovascular disease prevention.
Abstract:
Accelerated atherosclerosis and its long-term sequelae are a major cause of late mortality among patients with systemic lupus erythematosus (SLE). Traditional Framingham risk factors such as hypertension, hypercholesterolemia, diabetes, and smoking do not account in entirety for this risk. SLE specific factors like disease activity and duration, use of corticosteroids, presence of antiphospholipid antibodies, and others are important risk factors. SLE is considered a coronary heart disease; equivalent and aggressive management of all traditional risk factors is recommended. Despite their role in primary and secondary prevention in the general population, statins seem to have no effect on cardiovascular outcomes in adult or pediatric SLE populations. The use of hydroxychloroquine has a cardioprotective effect, and mycophenolate mofetil may reduce cardiovascular events based on basic science data and data from the transplant population. The role of vitamin D supplementation and treatment of hyperhomocysteinemia remain controversial, but due to the safety of therapy and the potential benefit, they remain as optional therapies.
Related Concept Videos
Atherosclerosis I: Introduction
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Atherosclerosis III: Management
Atherosclerosis IV: Nursing Management
Peripheral Artery Disease I: Introduction
Rheumatic Heart Disease I: Introduction